Immunogenicity and safety of concomitant bivalent COVID-19 and quadrivalent influenza vaccination: Implications of immune imprinting and interference.

Immunogenicity and safety of concomitant bivalent COVID-19 and quadrivalent influenza vaccination: Implications of immune imprinting and interference.

Publication date: Jan 20, 2024

Concomitant COVID-19 and influenza vaccination would be an efficient strategy. While the co-administration of monovalent COVID-19 and influenza vaccinations showed acceptable immunogenicity, it remains unknown whether the bivalent COVID-19 vaccine could intensify immune interference. We aimed to evaluate the immunogenicity and safety of concomitant BA. 5-based bivalent COVID-19 and influenza vaccination. An open-label, non-randomized clinical trial was conducted for 154 age- and sex-matched healthy adults between October and December 2022. Participants received either a concomitant bivalent COVID-19 mRNA booster and quadrivalent influenza vaccination (group C) or separate vaccinations (group S) at least four weeks apart. Solicited and unsolicited adverse events were reported up to 6 months post-vaccination. Immunogenicity was evaluated by anti-S IgG electrochemiluminescence immunoassay, focus reduction neutralization test and hemagglutination inhibition assay. Group C did not meet the non-inferiority criteria for the seroconversion rates of anti-S IgG and neutralizing antibodies against the wild-type SARS-CoV-2 strain compared to group S (44. 2% versus 46. 8%, difference of -2. 6% [95% CI -18 to 13. 4]; 44. 2% versus 57. 1%, difference of -13. 0% [95% CI -28. 9 to 2. 9]). However, group C showed a stronger post-vaccination neutralizing antibody response against Omicron BA. 5 (72. 7% versus 64. 9%). Post-vaccination geometric mean titers for SARS-CoV-2 and influenza strains were similar between groups, except for influenza B/Victoria. Most adverse events were mild and comparable between the study groups. Concomitant administration of bivalent COVID-19 mRNA and quadrivalent influenza vaccines showed tolerable safety profiles and sufficient immunogenicity, particularly attenuating immune imprinting induced by prior ancestral vaccine strains.

Concepts Keywords
December Administration
Influenza Bivalent
Mrna Concomitant
Unsolicited Covid
Vaccination Group
Immune
Immunogenicity
Imprinting
Influenza
Interference
Post
Quadrivalent
Safety
Showed
Vaccination

Semantics

Type Source Name
disease MESH COVID-19
disease MESH influenza
disease VO vaccination
disease VO efficient
disease VO COVID-19 vaccine
disease IDO assay
disease MESH seroconversion
disease VO influenza vaccines
disease VO vaccine

Original Article

(Visited 1 times, 1 visits today)